Demographics of Participants Receiving IM or IV Tixagevimab-Cilgavimab and Their Respective Pooled Placebo Arms
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); IM, intramuscularly; IV, intravenously; T-C, study group receiving active treatment with tixagevimab-cilgavimab.Unless otherwise indicated, data are expressed as No. (%) of participants. Percentages have been rounded and may not total 100. All participants were from sites in the US. IM administration consists of 600 mg (300 mg of each component) of monoclonal antibodies or 600 mg of placebo; IV administration, 300 mg (150 mg of each component) of monoclonal antibodies or 300 mg of placebo.Self-identified by participants.Includes American Indian or Alaska Native, multiple races or ethnicities, and other race or ethnicity.For most study enrollment into both IM and IV groups, persons who had received SARS-CoV-2 vaccines were considered lower risk. The single IV participant who was vaccinated enrolled under Protocol V3.0, when having received a vaccine was not included in risk stratification.Variant analysis was available for 202 participants in either the IV or IM trials: 115 (56.9%) had the Alpha variant, 23 (11.4%) had the Iota variant, 1 (0.5%) had the Delta variant, and 63 (31.2%) had a mix of other variants (eTable 7 in 